Report

The purpose of this study was to estimate the cost of generic drug development and approval. This study develops an analytical framework for examining the expected net present value (ENPV) (i.e., the difference between the present value of expected revenues over product life and cost of product development and approval) to a generic drug developer in different size drug markets.

This report aims to address the treatment care models for pregnant and postpartum women with SUD by describing opportunities to integrate OB/GYN and SUD care as well as barriers to integrated care delivery.

This is the fourth annual report to Congress describing results from the Certified Community Behavioral Health Clinic (CCBHC) evaluation. This report summarizes changes in CCBHC rates and costs from demonstration year one (DY1) to DY2, performance on quality measures in DY1, and the extent to which states provided quality bonus payments (QBPs) to CCBHCs for DY1.

This research report examines changes in Medicare fee-for-service Part B visits and use of telehealth in 2020 during the COVID-19 public health emergency (PHE) by beneficiary characteristics, provider specialty, and location. The analysis found that Medicare in-person visits dropped while telehealth visits increased significantly at the start of the pandemic.

Network adequacy is often defined as having enough providers within a health plan network to ensure reasonable and timely access to care. At a minimum, health plans should include a sufficient number of providers who deliver mental health and substance use disorder (SUD) services (collectively referred to in this report as behavioral health services) to support access to those services.

Dual eligible beneficiaries are an important subset of the Medicare and Medicaid populations because they have a high prevalence of chronic conditions and disabilities, substantial care needs, and high health care and long-term services and supports (LTSS) utilization and costs.

This resource guide for providers working with American Indian/Alaska Native people reentering their communities from incarceration, contains a compilation of federal resources, research, examples, and helpful considerations for facilitating a successful reentry. Related Products:

In 2016, the U.S. Department of Health and Human Services finalized its Guidelines for Regulatory Impact Analysis under the leadership of its Assistant Secretary for Planning Evaluation and Analytics Team. The Guidelines discuss strategies for characterizing the uncertainty in quantified effects as well as the potential impacts of non-quantified effects.

Many stakeholders and steps are involved in the life cycle of a prescription drug as it moves from chemical synthesis and formulation through dispensing or administration to patients. The specific steps involved in prescription drug supply chains often differ depending on the type of drug, the channel of distribution, and the patient’s source of prescription drug coverage.

This report provides an introduction to the supply chain for COVID-19 relevant medical devices and related challenges faced in ramping up their production during the COVID-19 pandemic.